AR and posterior cortical atrophy: Results from different clinical trials also support the use of AR antagonists, such as enzalutamide and apalutamide, as well as of androgen synthesis inhibitors, such as abiraterone, for the treatment of hormone-sensitive PCa [4,244,245,246,247,248,249,250,251].